Innovative Diagnostic Technology Karius offers a cutting-edge genomics-based microbial detection test that can identify over 1,000 pathogens from a single blood sample, providing a valuable tool for hospitals and laboratories seeking rapid and accurate infectious disease diagnosis.

Strong Funding and Growth With a recent Series C investment of $100 million led by prominent venture firms, Karius is positioned for rapid expansion and increased market penetration, creating opportunities for partnership and customer acquisition in the infectious disease diagnostics space.

Expanding Market Reach Karius is actively working to expand access to its advanced genomic diagnostics, especially tailored to combat antimicrobial resistance, which presents significant sales potential in healthcare providers aiming to improve infectious disease management.

Industry Recognition The inclusion of the Karius Test in the 2023 Duke-ISCVID Criteria for Infective Endocarditis enhances its credibility and adoption prospects among clinicians and hospitals focused on meeting emerging diagnostic standards.

Leadership and Strategic Positioning Recent hires of industry experts including former national health authority figures and experienced executives on the board strengthen Karius’s strategic direction and credibility, facilitating sales discussions with hospital networks and research institutions invested in innovative healthcare solutions.